Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the closing of a $16.6 million … Read More

FREDERICK, Md.–(BUSINESS WIRE)–Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. Food … Read More

FREDERICK, Md.–(BUSINESS WIRE)– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced it submitted an … Read More

FREDERICK, Md.–(BUSINESS WIRE)–Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Alex … Read More

Funding to Advance Development of Drug Candidates Targeting Heparin-Induced Thrombocytopenia and Type 1 Diabetes FREDERICK, Md.–(BUSINESS WIRE)–Veralox Therapeutics (“Veralox”), a preclinical stage company focused on accelerating the development of first-in-class … Read More

These four biotech startups reflect an ecosystem that is attracting founders, talent and capital. Frederick, Maryland continues to be a hotbed for biotech and a destination of choice for many … Read More